Avidity biosciences supports world facioscapulohumeral muscular dystrophy (fshd) day and presents preclinical data from fshd program

Oral presentation at fshd irc highlights preclinical data that demonstrated prevention of muscle weakness by reducing dux4 expression aoc 1020 on track to be in the clinic by end of 2022 for the treatment of fshd san diego , june 17, 2022 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), joins in activities to raise awareness for facioscapulohumeral muscular dystrophy (fshd) in support of world fshd day and highlights preclinical results supporting aoc 1020 for the treatment of fshd at the 29th annual fshd society international research congress (fshd irc) in orlando, florida. currently, there are no approved therapies for the treatment of fshd.
RNA Ratings Summary
RNA Quant Ranking